Last --
Change Today 0.00 / 0.00%
Volume 0.0
MDG On Other Exchanges
Symbol
Exchange
OTC US
Xetra
Xetra
All times are local (Market data is delayed by at least 15 minutes).

medigene ag (MDG) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIGENE AG (MDG)

Related News

No related news articles were found.

medigene ag (MDG) Related Businessweek News

No Related Businessweek News Found

medigene ag (MDG) Details

Medigene AG, a biotechnology company, researches and develops drugs to treat cancer and autoimmune diseases in Europe, Asia, and the United States. The company operates in two segments, Marketed Products and Drug Candidates. The Marketed Products segment offers Veregen, an ointment used to treat external genital warts. The Drug Candidates segment’s pipeline products include EndoTAG-1, a drug candidate that has completed two Phase II clinical trials for the treatment of pancreatic and breast cancer; and RhuDex, which is in Phase II clinical trial for the oral treatment of autoimmune diseases. It is also developing DC vaccines that are in Phase II clinical trials for treating prostate cancer; and Phase I/II clinical trials for the treatment of acute myeloid leukaemia. In addition, this segment is developing T cell receptor-(TCR) modified T cells, which is in pre-clinical trail for the treatment of advanced cancer; anti-TCR monoclonal antibodies that is in pre-clinical trail to treat T cell-mediated diseases, such as T cell leukaemia or auto-immune diseases; and adeno-associated virus-like particles, a technology platform for prophylactic and therapeutic vaccines, which is in pre-clinical trials. It has strategic partnership with Syncore Biotechnologies Ltd. The company was founded in 1994 and is headquartered in Martinsried, Germany.

57 Employees
Last Reported Date: 11/21/14
Founded in 1994

medigene ag (MDG) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: €563.0K
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €390.0K
Compensation as of Fiscal Year 2013.

medigene ag (MDG) Key Developments

MediGene AG Presents at 4th Annual Berenberg 1 - 1 Symposium @ German Equity Forum, Nov-26-2014

MediGene AG Presents at 4th Annual Berenberg 1 - 1 Symposium @ German Equity Forum, Nov-26-2014 . Venue: Maritim Hotel, Theodor-Heuss-Allee 3, 60486 Frankfurt am Main, Germany.

MediGene AG Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

MediGene AG reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the nine months, the company’s total revenue rose by 64% to EUR 8.4 million compared to EUR 5.1 million in 2013. EBITDA loss was reduced by 46% to EUR 3.3 million compared to EUR 6.1 million in 2013 due to the increase in revenue and all in all stable operating expenses. The net loss was reduced by 27% to EUR 5.6 million compared to EUR 7.7 million in 2013. Cash flow from operating activities decreased by 35% to EUR 7.1 million compared to EUR 10.8 million in 2013. Operating loss was EUR 3.9 million compared to EUR 6.7 million in 2013. For the quarter, the company reported total revenue of EUR 2.3 million compared to EUR 1.9 million, operating loss of EUR 1.8 million compared to EUR 2.0 million, net loss of EUR 2.8 million compared to EUR 2.1 million and EBITDA loss of EUR 1.6 million compared to EUR 1.8 million for the last year. The company confirmed its financial guidance for 2014. The company expects a further double-digit percentage increase in total revenue in 2014. Based on the forecasts provided by Medigene's sales partners, revenue achieved with Veregen(R) is likely to amount to between EUR 5 million and EUR 6 million. The EBITDA loss in 2014 is likely to be significantly reduced to EUR 4 million - EUR 6 million. According to the current business assumptions, Medigene's management expects the company to be financed until the end of 2016.

MediGene AG, Nine Months 2014 Earnings Call, Nov 21, 2014

MediGene AG, Nine Months 2014 Earnings Call, Nov 21, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDG:GR €0.00 EUR 0.00

MDG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $263.75 USD +2.85
Hemispherx Biopharma Inc $0.25 USD +0.007
Merck & Co Inc $58.98 USD +1.35
View Industry Companies
 

Industry Analysis

MDG

Industry Average

Valuation MDG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.2x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIGENE AG, please visit www.medigene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.